Ovid Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OVID research report →
About the company
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy.
- CEO
- Margaret Alexander
- IPO
- 2017
- Employees
- 23
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $354.77M
- P/E
- -7.78
- P/S
- 49.81
- P/B
- 1.00
- EV/EBITDA
- -10.92
- Div Yield
- 0.00%
- Gross Margin
- 99.51%
- Op Margin
- -670.25%
- Net Margin
- -339.33%
- ROE
- -22.51%
- ROIC
- -22.59%
- Revenue
- $7.25M · 1181.27%
- Net Income
- $-17,414,000 · 34.12%
- EPS
- $-0.24 · 35.14%
- Op Income
- $-42,439,000
- FCF YoY
- 31.58%
- 52W High
- $3.10
- 52W Low
- $0.33
- 50D MA
- $2.56
- 200D MA
- $1.94
- Beta
- 0.19
- Avg Volume
- 2.86M
Get TickerSpark's AI analysis on OVID
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | Greka Anna | other | 130,000 |
| Jun 15, 26 | Greka Anna | other | 0 |
| Apr 7, 26 | PAPADOPOULOS STELIOS | other | 17,578 |
| Apr 7, 26 | Friedman Bart | other | 8,789 |
| Apr 7, 26 | Fitzgerald Kevin Joseph | other | 17,578 |
| Mar 23, 26 | LEVIN JEREMY M | other | 47,333 |
| Mar 23, 26 | LEVIN JEREMY M | other | 47,333 |
| Feb 26, 26 | ALEXANDER MARGARET A. | other | 1,435,000 |
| Feb 23, 26 | ALEXANDER MARGARET A. | sell | 11,656 |
| Feb 26, 26 | PAPADOPOULOS STELIOS | other | 65,000 |
Our OVID coverage
Recent articles, reports, and earnings notes.
No research on OVID yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OVID report →Similar companies
Peers in the same neighborhood.